Inhibiting human integrin α5β1
Small molecule compounds targeting integrin α5β1 offer a promising oral therapy for pulmonary hypertension and heart failure, addressing the limitations of current treatments by providing effective inhibition of α5β1 integrin activity with improved safety and bioavailability.
Patent Information
- Application Number
- PCT/US2024/047672
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-08-26
- Filing Date
- 2024-09-20
- Publication Date
- 2025-03-27
AI Technical Summary
Current treatments for pulmonary hypertension, PAH, heart failure, and related diseases are limited by side effects, short drug half-life, and low bioavailability, necessitating the development of effective and safe oral α5β1 integrin inhibitors.
The development of small molecule compounds, such as those described in Formula (I), which specifically inhibit integrin α5β1, offering a potential oral therapy that can effectively target α5β1 integrin-mediated conditions without the need for frequent infusions.
These compounds demonstrate the ability to inhibit α5β1 integrin activity, providing a therapeutic benefit in treating diseases associated with increased expression or activity of integrin α5β1, such as pulmonary hypertension and heart failure, while minimizing adverse effects.